Biogen (NASDAQ:BIIB) Given New $233.00 Price Target at Royal Bank Of Canada

Biogen (NASDAQ:BIIB) had its price objective upped by Royal Bank Of Canada from $217.00 to $233.00 in a research note issued to investors on Monday, Marketbeat reports. Royal Bank Of Canada currently has an outperform rating on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Mizuho upped their price target on Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a report on Thursday, January 8th. Guggenheim upped their target price on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Company raised their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday. HSBC restated a “reduce” rating and set a $143.00 price objective (down previously from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Finally, Stifel Nicolaus lifted their target price on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday. Thirteen research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $206.21.

Biogen Stock Down 3.7%

BIIB stock opened at $193.81 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen has a 52-week low of $110.04 and a 52-week high of $202.41. The company has a 50-day moving average of $177.26 and a two-hundred day moving average of $157.48. The stock has a market capitalization of $28.43 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.70 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the company posted $3.44 earnings per share. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts anticipate that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 748 shares of Biogen stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider directly owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently modified their holdings of BIIB. Privium Fund Management B.V. acquired a new position in shares of Biogen during the 2nd quarter worth about $2,666,000. Nordea Investment Management AB raised its position in shares of Biogen by 5.7% in the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock valued at $15,810,000 after acquiring an additional 6,811 shares during the period. Convergence Investment Partners LLC bought a new position in Biogen during the 3rd quarter worth approximately $1,342,000. Pitcairn Co. acquired a new position in Biogen during the second quarter valued at approximately $936,000. Finally, Fluent Financial LLC acquired a new position in Biogen during the third quarter valued at approximately $3,578,000. Institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.